What is Ability Pharmaceuticals?
Ability Pharmaceuticals, established in 2009 and headquartered in Barcelona, Spain, is a clinical-stage biopharmaceutical company dedicated to advancing oncology treatments. The company is actively developing two drug candidates: ABTL0812, which is currently in phase 2 clinical trials, and ABTL0815, in preclinical development. This focus on novel therapies for unmet medical needs places Ability Pharmaceuticals at the forefront of biotech innovation in the Catalan and Spanish sectors. The company has previously established a territorial license agreement with SciClone Pharmaceuticals, Inc. for the development and marketing of ABTL0812 in Greater China, demonstrating its global commercial strategy.
How much funding has Ability Pharmaceuticals raised?
Ability Pharmaceuticals has raised a total of $7.6M across 1 funding round:
Other Financing Round
$7.6M
Other Financing Round (2024): $7.6M with participation from Inveready, The European Innovation Council, CTI Life Sciences Fund, and The CDTI
Key Investors in Ability Pharmaceuticals
Inveready
Inveready is a prominent Spanish financial services firm specializing in investment solutions and wealth management, known for its active role in the small and mid-market segments.
The European Innovation Council
The European Innovation Council operates within the Colleges & Universities sector, supporting innovation and technological advancement.
CTI Life Sciences Fund
CTI Life Sciences Fund is a Canadian venture capital firm with a strong focus on catalyzing innovative ideas and assets into scalable biotech companies, particularly in oncology.
What's next for Ability Pharmaceuticals?
With the recent major enterprise-level funding, Ability Pharmaceuticals is poised to accelerate the clinical development of its promising drug candidates, ABTL0812 and ABTL0815. This strategic investment will likely fuel further research and development, expand clinical trial operations, and potentially support regulatory submissions. The company's trajectory suggests a focus on scaling its operations and advancing its pipeline towards commercialization, aiming to solidify its position as a key player in the oncology therapeutics market.
See full Ability Pharmaceuticals company page
